A Novel Variant in Dopamine Receptor Type 2 Gene is Associated with Schizophrenia

摘要

Background. Being the primary target of antipsychotic therapy, dopamine receptor type 2 (DRD2) remains a point of interest in schizophrenia pathology. Polymorphisms in DRD2 have been shown to alter patients' response to antipsychotics. DRD2 SNP rs6275 (C > T) have found to be associated with schizophrenia in different populations; however, data remains inconsistent.